{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:07:19Z","timestamp":1779178039777,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["autonomicneuroscience.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autonomic Neuroscience"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.autneu.2026.103399","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:58:53Z","timestamp":1771433933000},"page":"103399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease"],"prefix":"10.1016","volume":"264","author":[{"given":"Shuai","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiewen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autneu.2026.103399_bb0005","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cpt.2277","article-title":"A disease progression model to quantify the nonmotor symptoms of Parkinson\u2019s disease in participants with leucine-rich repeat kinase 2 mutation","volume":"110","author":"Ahamadi","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.autneu.2026.103399_bb0010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar5429","article-title":"LRRK2 activation in idiopathic Parkinson\u2019s disease","volume":"10","author":"Di Maio","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.autneu.2026.103399_bb0015","article-title":"Leucine-rich repeat kinase 2 biomarkers for Parkinson\u2019s disease","volume":"482","author":"Dzamko","year":"2025","journal-title":"Biochem. J."},{"issue":"7","key":"10.1016\/j.autneu.2026.103399_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41582-025-01113-7","article-title":"\u03b1-Synuclein pathology in LRRK2 Parkinson disease","volume":"21","author":"Fyfe","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.autneu.2026.103399_bb0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s40478-019-0836-x","article-title":"Alzheimer\u2019s disease tau is a prominent pathology in LRRK2 Parkinson\u2019s disease","volume":"7","author":"Henderson","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.autneu.2026.103399_bb0030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","article-title":"Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease","volume":"72","author":"Kalia","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.autneu.2026.103399_bb0035","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-025-13086-0","article-title":"Impact of LRRK2 and GBA variants on orthostatic hypotension in patients with Parkinson\u2019s disease","volume":"272","author":"Liu","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.autneu.2026.103399_bb0040","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fnins.2020.00526","article-title":"Quantitative measurements of LRRK2 in human cerebrospinal fluid demonstrates increased levels in G2019S patients","volume":"14","author":"Mabrouk","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.autneu.2026.103399_bb0045","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/13543776.2024.2378076","article-title":"Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson\u2019s disease: a patent review of the literature to date","volume":"34","author":"Morez","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.autneu.2026.103399_bb0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neucli.2021.12.007","article-title":"Heart rate variability and sympathetic skin response for the assessment of autonomic dysfunction in leucine-rich repeat kinase 2 associated Parkinson\u2019s disease","volume":"52","author":"Nasri","year":"2022","journal-title":"Neurophysiol. Clin."},{"key":"10.1016\/j.autneu.2026.103399_bb0055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.autneu.2026.103399_bb0060","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/mds.27989","article-title":"Clinical and dopamine transporter imaging characteristics of leucine rich repeat kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson\u2019s disease participants in the Parkinson\u2019s progression markers initiative: a cross-sectional study","volume":"35","author":"Simuni","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.autneu.2026.103399_bb0065","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mds.26896","article-title":"Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson\u2019s disease","volume":"32","author":"Visanji","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.autneu.2026.103399_bb0070","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-024-00738-4","article-title":"Single molecule array measures of LRRK2 kinase activity in serum link Parkinson\u2019s disease severity to peripheral inflammation","volume":"19","author":"Yuan","year":"2024","journal-title":"Mol. Neurodegener."}],"container-title":["Autonomic Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1566070226000214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1566070226000214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:22:59Z","timestamp":1779175379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1566070226000214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":14,"alternative-id":["S1566070226000214"],"URL":"https:\/\/doi.org\/10.1016\/j.autneu.2026.103399","relation":{},"ISSN":["1566-0702"],"issn-type":[{"value":"1566-0702","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Autonomic Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autneu.2026.103399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103399"}}